Modulen Ibd Latte Polvere 400g

Product Information

Nestlé Health Science produces a range of foods for special medical purposes (FSMP) for use under medical supervision.

On one hand, this microbial-derived peptide improves the intestinal barrier by increasing Occludin expression; on the other hand, it alleviates Helicobacter pylori infection by inhibiting the futalosine pathway ( Figure 1, right panel) [ 60]. Even though causative explanations between microbiota and the immune system are not brought to light yet, the process is supported by intestinal permeability (IP) alterations. Indicated for use as a sole source of nutrition during the active phase of Crohn’s disease or nutritional support during the remission phase in malnourished patients. Corn Syrup, Casein (From Cow's Milk), Sugar (Sucrose), Milk Fat, Medium Chain Triglycerides(Coconut Oil), Corn Oil, And Less Than 2% Of Soy Lecithin, Potassium Citrate, Calcium Phosphate,Sodium Citrate, Calcium Carbonate, Magnesium Chloride, Potassium Hydroxide, Potassium Chloride,Sodium Ascorbate, Choline Bitartrate, Ferrous Sulfate,Magnesium Oxide, Dl-Alpha Tocopheryl Acetate,Zinc Sulfate, Niacinamide, Calcium Pantothenate.Modulen IBD powder is dosed and prepared according to the patient's age, weight and clinical condition.

Other derivatives may be valuable such as 15-hydroxyeicosatetraenoic acid, whose production by intestinal glial cells is defective in CD patients [ 59]. Modulen IBD is a unique whole-protein 100% casein-based, powdered formulation for the dietary management of the active phase of Crohn’s disease to be used as a sole source of nutrition and for nutritional support during the remission phase. Please note that parcels weighing over 2kg may be sent via courier due to Royal Mail weight restrictions.

However, as reported in the literature until now, the composition appears to be well balanced for CD remission and permits avoiding health status aggravation. People with Crohn's disease can ingest the powder during or before or after an outbreak of Crohn's disease. These studies have several limitations, while they are mainly retrospective or with no randomized control, and the endpoints were clinical remission rather than mucosal healing. Even if numerous exclusion diets were investigated, further clinical trials examining lactose, fibers, and gluten in IBD are required.